drugset / Trial / NCT00005057
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
Phase 1
Completed
National Human Genome Research Institute (NHGRI)
National Cancer Institute (NCI) · collab
Treatment
Summary
RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.
Timeline
- Start
- 2000-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganciclovir | Small molecule | — | Intravenous |
| Subject | adenovirus RSV-TK | Unknown | — | Other |